Literature DB >> 31263054

Frequency of Pathogenic Germline Variants in CDH1, BRCA2, CHEK2, PALB2, BRCA1, and TP53 in Sporadic Lobular Breast Cancer.

Christos Petridis1,2, Iteeka Arora1, Vandna Shah1, Charlotte L Moss1, Anca Mera1, Angela Clifford1, Cheryl Gillett1, Sarah E Pinder1, Ian Tomlinson3, Rebecca Roylance4, Michael A Simpson2, Elinor J Sawyer5.   

Abstract

BACKGROUND: Invasive lobular breast cancer (ILC) accounts for approximately 15% of invasive breast carcinomas and is commonly associated with lobular carcinoma in situ (LCIS). Both have been shown to have higher familial risks than the more common ductal cancers. However, there are little data on the prevalence of the known high and moderate penetrance breast cancer predisposition genes in ILC. The aim of this study was to assess the frequency of germline variants in CDH1, BRCA2, BRCA1, CHEK2, PALB2, and TP53 in sporadic ILC and LCIS diagnosed in women ages ≤60 years.
METHODS: Access Array technology (Fluidigm) was used to amplify all exons of CDH1, BRCA2, BRCA1, TP53, CHEK2, and PALB2 using a custom-made targeted sequencing panel in 1,434 cases of ILC and 368 cases of pure LCIS together with 1,611 controls.
RESULTS: Case-control analysis revealed an excess of pathogenic variants in BRCA2, CHEK2, PALB2, and CDH1 in women with ILC. CHEK2 was the only gene that showed an association with pure LCIS [OR = 9.90; 95% confidence interval (CI), 3.42-28.66, P = 1.4 × 10-5] with a larger effect size seen in LCIS compared with ILC (OR = 4.31; 95% CI, 1.61-11.58, P = 1.7 × 10-3).
CONCLUSIONS: Eleven percent of patients with ILC ages ≤40 years carried germline variants in known breast cancer susceptibility genes. IMPACT: Women with ILC ages ≤40 years should be offered genetic screening using a panel of genes that includes BRCA2, CHEK2, PALB2, and CDH1. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2019        PMID: 31263054     DOI: 10.1158/1055-9965.EPI-18-1102

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  9 in total

1.  New surveillance guidelines for Li-Fraumeni and hereditary TP53 related cancer syndrome: implications for germline TP53 testing in breast cancer.

Authors:  D Gareth Evans; Emma R Woodward
Journal:  Fam Cancer       Date:  2021-01       Impact factor: 2.375

2.  Germline Pathogenic Variants in Cancer Predisposition Genes Among Women With Invasive Lobular Carcinoma of the Breast.

Authors:  Siddhartha Yadav; Chunling Hu; Katherine L Nathanson; Jeffrey N Weitzel; David E Goldgar; Peter Kraft; Rohan D Gnanaolivu; Jie Na; Hongyan Huang; Nicholas J Boddicker; Nicole Larson; Chi Gao; Song Yao; Clarice Weinberg; Celine M Vachon; Amy Trentham-Dietz; Jack A Taylor; Dale R Sandler; Alpa Patel; Julie R Palmer; Janet E Olson; Susan Neuhausen; Elena Martinez; Sara Lindstrom; James V Lacey; Allison W Kurian; Esther M John; Christopher Haiman; Leslie Bernstein; Paul W Auer; Hoda Anton-Culver; Christine B Ambrosone; Rachid Karam; Elizabeth Chao; Amal Yussuf; Tina Pesaran; Jill S Dolinsky; Steven N Hart; Holly LaDuca; Eric C Polley; Susan M Domchek; Fergus J Couch
Journal:  J Clin Oncol       Date:  2021-10-21       Impact factor: 44.544

Review 3.  Consensus Recommendations of the German Consortium for Hereditary Breast and Ovarian Cancer.

Authors:  Kerstin Rhiem; Bernd Auber; Susanne Briest; Nicola Dikow; Nina Ditsch; Neda Dragicevic; Sabine Grill; Eric Hahnen; Judit Horvath; Bernadette Jaeger; Karin Kast; Marion Kiechle; Elena Leinert; Susanne Morlot; Michael Püsken; Dieter Schäfer; Sarah Schott; Christopher Schroeder; Ulrike Siebers-Renelt; Christine Solbach; Nana Weber-Lassalle; Isabell Witzel; Christine Zeder-Göß; Rita K Schmutzler
Journal:  Breast Care (Basel)       Date:  2021-07-19       Impact factor: 2.268

4.  A Genome-First Approach to Estimate Prevalence of Germline Pathogenic Variants and Risk of Pancreatic Cancer in Select Cancer Susceptibility Genes.

Authors:  Esteban Astiazaran-Symonds; Jung Kim; Jeremy S Haley; Sun Young Kim; H Shanker Rao; Regeneron Genetics Center; David J Carey; Douglas R Stewart; Alisa M Goldstein
Journal:  Cancers (Basel)       Date:  2022-07-02       Impact factor: 6.575

5.  Identification of hereditary breast and ovarian cancer germline variants in Granada (Spain): NGS perspective.

Authors:  María Molina-Zayas; Carmen Garrido-Navas; Jose Luis García-Puche; Julian Barwell; Susana Pedrinaci; Margarita Martínez Atienza; Susana García-Linares; Tomás de Haro-Muñoz; Jose Antonio Lorente; M Jose Serrano; Antonio Poyatos-Andújar
Journal:  Mol Genet Genomics       Date:  2022-04-22       Impact factor: 2.980

Review 6.  Hereditary diffuse gastric cancer: updated clinical practice guidelines.

Authors:  Vanessa R Blair; Maybelle McLeod; Fátima Carneiro; Daniel G Coit; Johanna L D'Addario; Jolanda M van Dieren; Kirsty L Harris; Nicoline Hoogerbrugge; Carla Oliveira; Rachel S van der Post; Julie Arnold; Patrick R Benusiglio; Tanya M Bisseling; Alex Boussioutas; Annemieke Cats; Amanda Charlton; Karen E Chelcun Schreiber; Jeremy L Davis; Massimiliano di Pietro; Rebecca C Fitzgerald; James M Ford; Kimberley Gamet; Irene Gullo; Richard H Hardwick; David G Huntsman; Pardeep Kaurah; Sonia S Kupfer; Andrew Latchford; Paul F Mansfield; Takeshi Nakajima; Susan Parry; Jeremy Rossaak; Haruhiko Sugimura; Magali Svrcek; Marc Tischkowitz; Toshikazu Ushijima; Hidetaka Yamada; Han-Kwang Yang; Adrian Claydon; Joana Figueiredo; Karyn Paringatai; Raquel Seruca; Nicola Bougen-Zhukov; Tom Brew; Simone Busija; Patricia Carneiro; Lynn DeGregorio; Helen Fisher; Erin Gardner; Tanis D Godwin; Katharine N Holm; Bostjan Humar; Caroline J Lintott; Elizabeth C Monroe; Mark D Muller; Enrique Norero; Yasmin Nouri; Joana Paredes; João M Sanches; Emily Schulpen; Ana S Ribeiro; Andrew Sporle; James Whitworth; Liying Zhang; Anthony E Reeve; Parry Guilford
Journal:  Lancet Oncol       Date:  2020-08       Impact factor: 41.316

7.  Li-Fraumeni syndrome in Tunisian carriers with different and rare tumor phenotype: genotype-phenotype correlation.

Authors:  Hela Sassi; Rym Meddeb; Mohamed Aziz Cherif; Chiraz Nasr; Aouatef Riahi; Samia Hannachi; Neila Belguith; Ridha M'rad
Journal:  BMC Med Genomics       Date:  2022-03-04       Impact factor: 3.063

8.  Extended gene panel testing in lobular breast cancer.

Authors:  Elke M van Veen; D Gareth Evans; Elaine F Harkness; Helen J Byers; Jamie M Ellingford; Emma R Woodward; Naomi L Bowers; Andrew J Wallace; Sacha J Howell; Anthony Howell; Fiona Lalloo; William G Newman; Miriam J Smith
Journal:  Fam Cancer       Date:  2021-03-25       Impact factor: 2.375

9.  A Novel Gene Prognostic Signature Based on Differential DNA Methylation in Breast Cancer.

Authors:  Chunmei Zhu; Shuyuan Zhang; Di Liu; Qingqing Wang; Ningning Yang; Zhewen Zheng; Qiuji Wu; Yunfeng Zhou
Journal:  Front Genet       Date:  2021-12-08       Impact factor: 4.599

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.